injection site for semaglutide Where to Inject Semaglutide: Does It Make a Difference?

Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished

25.08

★★★★☆4.8 (126)

Phase 2 Trial of Retatrutide for Obesity

24.24

★★★★★4.9 (98)

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight https://t.co/Yh0vGKq692

24.22

★★★★★5.0 (157)

Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:

27.54

★★★★★4.7 (84)

Lilly's triple agonist delivers up to 71.2 lbs of weight loss

27.94

★★★★★4.9 (203)

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial @NEJM Amazing 24% weight reduction with new obesity drug (-24.2% change in body weight at 48 weeks) Obesity treatment with Triple–Hormone-Receptor Agonist #

26.92

★★★★★5.0 (176)

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

29.65

★★★★★4.8 (132)